These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer. Duffy MJ; Duggan C Clin Biochem; 2004 Jul; 37(7):541-8. PubMed ID: 15234235 [TBL] [Abstract][Full Text] [Related]
3. Urokinase-type plasminogen activator system and breast cancer (Review). Han B; Nakamura M; Mori I; Nakamura Y; Kakudo K Oncol Rep; 2005 Jul; 14(1):105-12. PubMed ID: 15944776 [TBL] [Abstract][Full Text] [Related]
4. Tumour-associated urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in normal and neoplastic tissues of patients with squamous cell cancer of the oral cavity - clinical relevance and prognostic value. Hundsdorfer B; Zeilhofer HF; Bock KP; Dettmar P; Schmitt M; Kolk A; Pautke C; Horch HH J Craniomaxillofac Surg; 2005 Jun; 33(3):191-6. PubMed ID: 15878520 [TBL] [Abstract][Full Text] [Related]
5. Expression of active plasminogen activator inhibitor-1 reduces cell migration and invasion in breast and gynecological cancer cells. Whitley BR; Palmieri D; Twerdi CD; Church FC Exp Cell Res; 2004 Jun; 296(2):151-62. PubMed ID: 15149846 [TBL] [Abstract][Full Text] [Related]
6. Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer. Harbeck N; Kates RE; Gauger K; Willems A; Kiechle M; Magdolen V; Schmitt M Thromb Haemost; 2004 Mar; 91(3):450-6. PubMed ID: 14983219 [TBL] [Abstract][Full Text] [Related]
7. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion. Hildenbrand R; Schaaf A Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473 [TBL] [Abstract][Full Text] [Related]
8. Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma. Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Geurts-Moespot A; van Tienoven DT; Beex LV; Sweep FC Cancer; 2004 Aug; 101(3):486-94. PubMed ID: 15274061 [TBL] [Abstract][Full Text] [Related]
9. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA. Biermann JC; Holzscheiter L; Kotzsch M; Luther T; Kiechle-Bahat M; Sweep FC; Span PN; Schmitt M; Magdolen V Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793 [TBL] [Abstract][Full Text] [Related]
10. Urokinase plasminogen activator and plasminogen activator inhibitor type-1 in nonsmall-cell lung cancer: relation to prognosis and angiogenesis. Offersen BV; Pfeiffer P; Andreasen P; Overgaard J Lung Cancer; 2007 Apr; 56(1):43-50. PubMed ID: 17207889 [TBL] [Abstract][Full Text] [Related]
11. [The role of cathepsins and the plasminogen activator/inhibitor system in colorectal cancer]. Herszényi L; Farinati F; Plebani M; István G; Sápi Z; Carraro P; De Paoli M; Naccarato R; Tulassay Z Orv Hetil; 1999 Aug; 140(33):1833-6. PubMed ID: 10489782 [TBL] [Abstract][Full Text] [Related]
12. [Role of PAI-1 plasminogen activator inhibitor in tumor invasion and angiogenesis]. Bajou K Bull Mem Acad R Med Belg; 2002; 157(5-6):313-8. PubMed ID: 12557575 [TBL] [Abstract][Full Text] [Related]
13. Expression of plasminogen activator inhibitors type 1 and type 3 and urokinase plasminogen activator protein and mRNA in breast cancer. Castelló R; Landete JM; España F; Vázquez C; Fuster C; Almenar SM; Ramón LA; Radtke KP; Estellés A Thromb Res; 2007; 120(5):753-62. PubMed ID: 17258797 [TBL] [Abstract][Full Text] [Related]
14. [u-Plasminogen activator (urinary plasminogen activator, urokinase) (uPA) and its PA-1 type 1 inhibitor are not only prognostically but also predictively significant and support clinical decisions on therapy in primary carcinoma of the breast]. Harbeck N; Thomssen C Zentralbl Gynakol; 2003 Sep; 125(9):362-7. PubMed ID: 14569518 [TBL] [Abstract][Full Text] [Related]
15. Wound-induced migration of MDA-MB-435 and SKOV-3 cancer cells is regulated by plasminogen activator inhibitor-1. Whitley BR; Church FC Int J Oncol; 2005 Sep; 27(3):749-57. PubMed ID: 16077925 [TBL] [Abstract][Full Text] [Related]
16. Role of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) for prognosis in endometrial cancer. Steiner E; Pollow K; Hasenclever D; Schormann W; Hermes M; Schmidt M; Puhl A; Brulport M; Bauer A; Petry IB; Koelbl H; Hengstler JG Gynecol Oncol; 2008 Mar; 108(3):569-76. PubMed ID: 18222533 [TBL] [Abstract][Full Text] [Related]
17. Metastasis of transgenic breast cancer in plasminogen activator inhibitor-1 gene-deficient mice. Almholt K; Nielsen BS; Frandsen TL; Brünner N; Danø K; Johnsen M Oncogene; 2003 Jul; 22(28):4389-97. PubMed ID: 12853975 [TBL] [Abstract][Full Text] [Related]